维格列汀联合吡格列酮治疗2型糖尿病的效果及其对血糖、8—羟基脱氧鸟苷和炎症因子的影响(1)
[摘要] 目的 探讨维格列汀与吡格列酮治疗2型糖尿病的效果及其对血糖水平、8-羟基脱氧鸟苷(8-OHdG)和炎症因子水平的影响。 方法 选取2014年1月～2015年6月于四川省人民医院崇州分院内分泌科诊治的58例2型糖尿病患者为研究对象，以随机数字表法将患者分为维格列汀组(单独组)和维格列汀+吡格列酮组(联合组)，每组各58例。分别比较两组患者的血糖指标及血糖波动、8-OHdG水平和炎症因子水平的变化。 结果 治疗后，两组空腹血糖(FPG)、餐后2 h血糖(2hPBG)、糖化血红蛋白(HbA1c)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)和8-OHdG水平较治疗前显著降低(P < 0.05)；联合组血糖指标、炎症因子及8-OHdG的改善程度均明显优于单独组(P < 0.05)；两组血糖标准差(SDBG)、日内平均血糖波动幅度(MAGE)、血糖波动最大幅度(LAGE)及平均餐后血糖波动幅度(MPPGE)水平较治疗前显著下降(P < 0.05)，联合组动态血糖监测水平的下降程度明显高于单独组(P < 0.05)。联合组不良反应发生率低于单独组，但两组比较差异无统计学意义(χ2=0.099，P = 0.753)。 结论 维格列汀联合吡格列酮治疗2型糖尿病效果良好，能降低8-OHdG水平和炎症因子水平。
[关键词] 维格列汀；吡格列酮；2型糖尿病；血糖；8-羟基脱氧鸟苷；炎症因子
[中图分类号] R587 [文献标识码] A [文章编号] 1673-7210(2016)03(c)-0153-04
[Abstract] Objective To investigate the therapeutic effects of Vildagliptin combined with Pioglitazone on type 2 diabetes mellitus and its influence on the levels of blood glucose， 8-OHdG and inflammatory factors. Methods Fifty-eight cases of patients with type 2 diabetes mellitus in the Department of Endocrinology of Chongzhou Branch of Sichuan People's Hospital from January 2014 to June 2015 were selected as the research objects. The patients were randomly divided into the Vildagliptin group (single group) and Vildagliptin + Pioglitazone group (combined group) according to random number table， each group had 58 cases. The levels of glycemic indexes， glycemic fluctuation， 8-OHdG and inflammatory factors were compared between the two groups. Results After treatment， the glycemic indexes， FPG， 2hPBG， HbA1c and inflammatory cytokines， IL-6， TNF-α and 8-OHdG were all lower than those before treatment (P < 0.05)； the improvement of glycemic indexes， 8-OHdG and inflammatory factors in the combined group were significantly better than those of single group (P < 0.05). The levels of standard deviation of blood glucose (SDBG)， mean amplitude of glycemic excursions (MAGE)， largest amplitude glycemic excursions (LAGE) and mean postprandial glucose excursions (MPPGE) of the two groups were significantly decreased compared with before treatment (P < 0.05)， the descending degree of combined group was significantly higher than that of single group (P < 0.05). The incidence of adverse reactions of combined group was lower than that of single group， but the difference between the two groups was not significant (χ2=0.099， P = 0.753). Conclusion Vildagliptin combined with Pioglitazone shows better clinical efficacy on type 2 diabetes mellitus， which can decrease the levels of 8-OHdG and inflammatory factors., 百拇医药(高启蓉 李蓉 罗薛松 罗一川)
[关键词] 维格列汀；吡格列酮；2型糖尿病；血糖；8-羟基脱氧鸟苷；炎症因子
[中图分类号] R587 [文献标识码] A [文章编号] 1673-7210(2016)03(c)-0153-04
[Abstract] Objective To investigate the therapeutic effects of Vildagliptin combined with Pioglitazone on type 2 diabetes mellitus and its influence on the levels of blood glucose， 8-OHdG and inflammatory factors. Methods Fifty-eight cases of patients with type 2 diabetes mellitus in the Department of Endocrinology of Chongzhou Branch of Sichuan People's Hospital from January 2014 to June 2015 were selected as the research objects. The patients were randomly divided into the Vildagliptin group (single group) and Vildagliptin + Pioglitazone group (combined group) according to random number table， each group had 58 cases. The levels of glycemic indexes， glycemic fluctuation， 8-OHdG and inflammatory factors were compared between the two groups. Results After treatment， the glycemic indexes， FPG， 2hPBG， HbA1c and inflammatory cytokines， IL-6， TNF-α and 8-OHdG were all lower than those before treatment (P < 0.05)； the improvement of glycemic indexes， 8-OHdG and inflammatory factors in the combined group were significantly better than those of single group (P < 0.05). The levels of standard deviation of blood glucose (SDBG)， mean amplitude of glycemic excursions (MAGE)， largest amplitude glycemic excursions (LAGE) and mean postprandial glucose excursions (MPPGE) of the two groups were significantly decreased compared with before treatment (P < 0.05)， the descending degree of combined group was significantly higher than that of single group (P < 0.05). The incidence of adverse reactions of combined group was lower than that of single group， but the difference between the two groups was not significant (χ2=0.099， P = 0.753). Conclusion Vildagliptin combined with Pioglitazone shows better clinical efficacy on type 2 diabetes mellitus， which can decrease the levels of 8-OHdG and inflammatory factors., 百拇医药(高启蓉 李蓉 罗薛松 罗一川)